EDSA: Edesa Biotech Inc Price to Sales
The active growth of clinical trials for ARDS therapy correlates with the price action of Edesa Biotech, Inc. (EDSA). The price-to-sales ratio reflects the impact of partnerships with government agencies for the development of immunotherapeutic drugs and the potential for monopoly pricing power regarding treatments for dermatological pathologies. The current level of determines this parameter, helping investors balance the risk of overpaying for the business relative to its actual sales.
Metric breakdowns and analytics for Edesa (EDSA)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Debt to Capital Edesa Biotech, Inc.|EDSA - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Edesa Biotech Corp|EDSA - Company Aggregate Debts|Debts to Book Capitalization Edesa|EDSA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Edesa Biotech|Quick Liquidity edesabiotech.com
- earnings and multiples data:
EDSA - Net Profit|Company Profit Forecast Edesa Biotech, Inc.|EDSA - Price to Earnings Ratio|Projected Price to Earnings Ratio Edesa Biotech Inc|EDSA - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Edesa|EDSA - Operating profit EBITDA|Net earnings per one share for the last twelve months Edesa Biotech|EDSA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months edesabiotech.com|EDSA - Earnings growth in current year|Expected earnings per share trend next year Edesa Biotech, Inc.
- issuer revenue and sales details:
General company analysis:EDSA edesabiotech.com
Intellectual property protection for molecular compounds provides Edesa Biotech, Inc. (EDSA) with a long-term competitive advantage. This asset base correlates with revenue, forming the basis for calculating the value of each sales unit. The multiplier determines the extent to which market capitalization aligns with actual revenue generation rates amid costly clinical trials. An analysis of the P/S market multiplier allows for the timely detection of valuation overheating and the adjustment of investment risks.
Who Edesa Biotech, Inc. competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Price to Sales Protagonist Corp|IMVT: P/S Multiple|Market Cap to Revenue Ratio KNSA|GRFS (Grifols) - P/S Multiple|Price to Sales Adaptive Biotech ADPT|Price-to-Revenue Ratio Celldex (CLDX)|Price-to-Revenue Coefficient Aurinia Corp|P/S Multiple BCRX (BioCryst)|P/S Multiple veratx.com VERA|DNTH: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PHVS (Pharvaris NV)|ABCL: P/S Multiple|TRML (Tourmaline) - Price-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|pharming.com (PHAR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB - Price to Sales|Zenas Biopharma, Inc. - Market Cap to Revenue|Market Cap to Sales Volume IMNM (Immunome Bio)|Gossamer Bio, Inc. - P/S Multiple|Price to Sales kalvista.com|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharma|SVRA (Savara Corp) - P/S Multiple|RIGL: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue ANAB (AnaptysBio, Inc.)|ATXS (astriatx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENGN (enGene)|Price-to-Revenue Coefficient RAPT Therapeutics Inc. (RAPT)|JBIO - Price-to-Revenue Ratio|ACRS (Aclaris Therapeutics, Inc) - Market Cap to Revenue Ratio|KYTX: P/S Multiple|Market Cap to Revenue tizianalifesciences.com|Market Cap to Revenue CABA|Ventyx Biosciences Inc. (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|AVTX - Price to Sales|P/S Multiple ELDN (Eledon Pharmaceuticals)|AGEN: Market Cap to Revenue Ratio|CLYM - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Zura Bio Ltd ZURA|ATYR: P/S Multiple|Adagene Inc. (ADAG) - P/S Multiple|Price-to-Revenue Ratio ImageneBio|Shattuck Therapeutics - Price-to-Sales Ratio|P/S Multiple EQ|CNTB (connectbiopharm.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple IMUX (Immunic)|P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio XFOR (x4pharma.com)|adicetbio.com (ACET) - Price-to-Revenue Ratio|Market Cap to Revenue Celularity|INMB (INmune Bio Corp) - P/S Multiple|P/S Multiple Barinthus Biotherapeutics Corp|Market Cap to Revenue KZR (Kezar Life Sciences)|SABS (sabbiotherapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple AKTX (Akari Therapeutics Plc)|Price-to-Revenue Coefficient Enlivex Therapeutics Ltd (ENLV)|QTTB - Price-to-Revenue Ratio|GeoVax Corp (GOVX) - Market Cap to Revenue|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Carisma Therapeutics Inc.|Market Cap to Revenue XTLB|P/S Multiple Bolt Bio|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple AIM (AIM ImmunoTech Inc.)|Aditxt Inc. (ADTX) - Price to Sales|GRI Bio - P/S Multiple|Price to Sales XORTX Therapeutics Inc|HIND: P/S Multiple|Market Cap to Revenue Ratio REVB|INDP (Indaptus Therapeutics) - P/S Multiple|Price to Sales scinai.com SCNI|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|Price-to-Revenue Coefficient affimed.com|P/S Multiple ALLK (Allakos)|P/S Multiple HOOKIPA Pharma, Inc. HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iteostherapeutics.com)|OCEA: P/S Multiple|TCBP (TC BioPharm (Holdings) Plc) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
